Atea Pharmaceuticals (AVIR) Set to Announce Earnings on Wednesday

Posted by Patrick Bannon on Aug 6th, 2024

Atea Pharmaceuticals (NASDAQ:AVIR – Get Free Report) will be posting its quarterly earnings results after the market closes on Wednesday, August 7th. Analysts expect Atea Pharmaceuticals to post earnings of ($0.76) per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Atea Pharmaceuticals (NASDAQ:AVIR – Get Free Report) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.14). On average, analysts expect Atea Pharmaceuticals to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Atea Pharmaceuticals Price Performance

NASDAQ AVIR traded up $0.04 on Tuesday, hitting $3.32. 55,927 shares of the company’s stock were exchanged, compared to its average volume of 344,931. The firm has a market cap of $279.62 million, a price-to-earnings ratio of -1.66 and a beta of 0.17. The firm’s 50-day moving average price is $3.58 and its two-hundred day moving average price is $3.81. Atea Pharmaceuticals has a fifty-two week low of $2.77 and a fifty-two week high of $4.60.

Insider Activity at Atea Pharmaceuticals

In other Atea Pharmaceuticals news, Director Bruce Polsky sold 17,544 shares of the firm’s stock in a transaction on Thursday, June 20th. The stock was sold at an average price of $3.49, for a total value of $61,228.56. Following the completion of the sale, the director now owns 65,606 shares of the company’s stock, valued at $228,964.94. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 17.80% of the company’s stock.

About Atea Pharmaceuticals

(Get Free Report)

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.